MRNA Moderna

Q3 2025 10-Q

Filed: Nov 6, 2025Period ending Sep 30, 2025

Health Care

Biological Products, (No Diagnostic Substances)SEC EDGAR

Moderna (MRNA) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• Section 'mda' was empty or not found.

Risk Factors

• No material changes to risk factors from 2024 Form 10-K
• Continued dependency on successful development and commercialization of vaccine candidates

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$1.0B

▼ -45.4% YoY▲ +615.5% QoQ

Net Income

-$200M

▼ -1638.5% YoY▲ +75.8% QoQ

Operating Margin

-25.6%

▼ -2183bp YoY▲ +61314bp QoQ

Net Margin

-19.7%

▼ -2038bp YoY▲ +56130bp QoQ

ROE

-2.1%

Total Assets

$12.1B

EPS (Diluted)

$-0.51

▼ -1375.0% YoY▲ +75.9% QoQ

Operating Cash Flow

-$847M

▲ +45.9% YoY▲ +7.8% QoQ

Source: XBRL data from Moderna Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Moderna Quarterly Reports

Q2 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Moderna

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.